HOME › DRUGS › TREMELIMUMAB
ACTIVE SUBSTANCE / INN

TREMELIMUMAB

Brand name(s): Tremelimumab AstraZeneca, Imjudo
EMA LISTED
WITHDRAWN
AUTHORISED
Carcinoma, Hepatocellular;Carcinoma, Non-Small-Cell Lung
Carcinoma, Non-Small-Cell Lung
ACTIVE SUBSTANCE
Tremelimumab
REGULATORS
EMA
SPONSORS / MAH
AstraZeneca AB
TOTAL APPLICATIONS
2
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
ImjudoAstraZeneca ABAuthorised20/02/2023Carcinoma, Hepatocellular;Carcinoma, Non-Small-Cell Lung
Tremelimumab AstraZenecaAstraZeneca ABWithdrawn20/02/2023Carcinoma, Non-Small-Cell Lung

FULL INTELLIGENCE ON TREMELIMUMAB

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →